Parallax Volatility Advisers
BCTX

Parallax Volatility Advisers’s Briacell Therapeutics BCTX Stock Holding History

Parallax Volatility Advisers’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-132
Closed -$112K – 2866
2022
Q3 		$112K Buy
+132
New +$132K ﹤0.01% 2447

Other funds holding BCTX

LCM
Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return
KJHP
K.J. Harrison & Partners Toronto, Ontario, Canada $608M AUM 45.31% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
STA
Summit Trail Advisors New York $6.98B AUM 19.51% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
CWP
Concord Wealth Partners Abingdon, Virginia $873M AUM 24.02% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
N
Natixis Paris, France $28B AUM 26.79% 1-Year Est. Return

Parallax Volatility Advisers's BCTX Position: Q4 2022 in Review

Parallax Volatility Advisers sold out of Briacell Therapeutics (BCTX) in Q4 2022, closing a stake of 13 shares — an estimated $11K sold.

Parallax Volatility Advisers first reported a position in BCTX in Q3 2022 and held it in 1 quarter. The position peaked at $11K in Q3 2022. 18 funds tracked by Wall St. Rank hold BCTX as of Q4 2022.

  • Parallax Volatility Advisers reported no remaining Briacell Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Parallax Volatility Advisers sold 13 Briacell Therapeutics shares in Q4 2022, an estimated $11K.
  • Parallax Volatility Advisers first reported a position in Briacell Therapeutics in Q3 2022 and held it in 1 quarter.
  • Parallax Volatility Advisers's Briacell Therapeutics position peaked at $11K in Q3 2022.
  • 18 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q4 2022.

Based on Parallax Volatility Advisers's 13F filing for Q4 2022, filed 14 Feb 2023.